TENX Share Price | Tenax Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Tenax Therapeutics, Inc. do?

Overview:Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the critical care market, specifically targeting conditions such as acutely decompensated heart failure. The company operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap entity.Financial Snapshot:Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025)Market cap: USD 23.56 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Dividend Yield: 0.00%Debt Equity: -1.02Return on Equity: -22.15%Price to Book: 0.22Contact Details:Address: One Copley Parkway, Suite 490, MORRISVILLE NC: 27560Tel: ['1 919 8064414', '1 919 8552112']Fax: 1 302 6745266Website: http://www.tenaxthera.com/

Q: Is Tenax Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Tenax Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the overall positive sentiment. The KST is bullish on both weekly and monthly time frames, while the OBV indicates a mildly bullish stance in both periods as well. However, the daily moving averages show a mildly bearish trend, which tempers the overall bullish outlook. The Dow Theory presents a mildly bullish signal on the weekly and mildly bearish on the monthly, indicating mixed signals.In terms of performance, Tenax has outperformed the S&P 500 over the past week and month, returning 4.40% and 6.66% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns are significantly negative over 3 and 5 years, contrasting sharply with the S&P 500's positive performance in those periods. Overall, the current technical stance is mildly bullish, driven by the positive MACD and KST indicators, despite some bearish signals from moving averages.

Results Declared: Tenax Therapeutics, Inc. has declared results on 10 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

225.67 k

Shareholding (Dec 2025)

FII

9.67%

Held by 11 FIIs

DII

65.17%

Held by 9 DIIs

Promoter

17.19%

How big is Tenax Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Tenax Therapeutics, Inc. has a market capitalization of 23.56 million and reported net sales of 0.00 million with a net profit of -24.22 million over the last four quarters. Shareholder's funds were 91.99 million, and total assets were 96.69 million.

View full answer

What does Tenax Therapeutics, Inc. do?

22-Jun-2025

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for critical care, particularly acutely decompensated heart failure. It has a market cap of $23.56 million and reported a net profit loss of $10 million as of March 2025.

View full answer

Who are in the management team of Tenax Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Tenax Therapeutics, Inc. includes Dr. Ronald Blanck (Independent Chairman), Mr. Anthony DiTonno (CEO), and Directors Mr. Steven Boyd, Mr. Keith Maher, Mr. James Mitchum, Mr. Gerald Proehl, and Mr. Gregory Pepin. They oversee the company's strategic direction and operations.

View full answer

Is Tenax Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Tenax Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and KST indicators, despite some bearish signals from daily moving averages and mixed Dow Theory signals, while outperforming the S&P 500 in the short term but lagging in the long term.

View full answer

Compare Tenax Therapeutics, Inc. with Similar Stocks

Inhibikase Therapeutics, Inc.Pulmatrix, Inc.Galera Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 240 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-45.03%

Price to Book

2.50

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-16 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.31%

6 Months

118.53%

1 Year

117.2%

2 Years

273.56%

3 Years

2612.93%

4 Years

-98.67%

5 Years

-99.55%

Tenax Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-222.82%

EBIT to Interest (avg)

-18.13

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.50

EV to EBIT

-2.99

EV to EBITDA

-2.99

EV to Capital Employed

-44.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-45.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 6 Schemes (7.96%)

Foreign Institutions

Held by 11 Foreign Institutions (9.67%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -146.03% vs -96.88% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.40",
          "val2": "-7.30",
          "chgp": "-124.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.50",
          "val2": "-6.30",
          "chgp": "-146.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -198.86% vs -128.57% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.40",
          "val2": "-19.50",
          "chgp": "-189.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.60",
          "val2": "-17.60",
          "chgp": "-198.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.40

-7.30

-124.66%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-15.50

-6.30

-146.03%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -146.03% vs -96.88% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-56.40

-19.50

-189.23%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-52.60

-17.60

-198.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -198.86% vs -128.57% in Dec 2024

All Annual Results

Company CV

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Company Coordinates

Company Details

One Copley Parkway, Suite 490 , MORRISVILLE NC : 27560

Tel: 1 919 80644141 919 8552112

http://www.tenaxthera.com/

Registrar Details